Frontotemporal dementia (FTD) is typified by behavioral and cognitive changes manifested as altered social comportment and impaired memory performance. To investigate the neurodegenerative consequences of progranulin gene (GRN) mutations, which cause an inherited form of FTD, we used previously generated progranulin knockout mice (Grn−/−). Specifically, we characterized two cohorts of early and later middle-aged wild type and knockout mice using a battery of tests to assess neurological integrity and behavioral phenotypes analogous to FTD. The Grn−/− mice exhibited reduced social engagement and learning and memory deficits. Immunohistochemical approaches were used to demonstrate the presence of lesions characteristic of frontotemporal lobar degeneration (FTLD) with GRN mutation including ubiquitination, microgliosis, and reactive astrocytosis, the pathological substrate of FTD. Importantly, Grn−/− mice also have decreased overall survival compared to Grn+/+ mice. These data suggest that the Grn−/− mouse reproduces some core features of FTD with respect to behavior, pathology, and survival. This murine model may serve as a valuable in vivo model of FTLD with GRN mutation through which molecular mechanisms underlying the disease can be further dissected.
Introduction
Frontotemporal dementia (FTD) represents 5-20% of all dementia cases and is the second most frequent dementia in people under the age of 65 years (Neary et al., 1998) . Frontotemporal lobar degeneration (FTLD), the pathology causing FTD, is heterogeneous. Three FTD phenotypes are recognized: behavioral variant FTD (bvFTD), primary progressive aphasia (PPA) and semantic dementia (SD); these are initially characterized by changes in behavior, personality, and language with dementia and parkinsonism appearing late in the disease (McKhann et al., 2001) . Behavioral changes include altered social comportment, lack of motivation, withdrawal, and apathy. Memory deficits are manifested by impaired social learning and memory performance. Dominantly inherited FTD comprises 5-10% of all FTD cases, with mutations in the progranulin gene (GRN) accounting for 53% of familial FTD (http://www.molgen.ua.ac.be/FTDMutations). Mutations in the progranulin gene co-segregate with affected individuals in these kindreds and have also been identified in cases of sporadic FTD (Baker et al., 2006; Behrens et al., 2007; Cruts et al., 2006; Gass et al., 2006; Mesulam et al., 2007; Mukherjee et al., 2006) . The pathology of FTLD with GRN mutation is characterized by focal atrophy of the frontal and temporal lobes and the striatum is frequently affected. Microscopy reveals the signature lesions of all FTLD entities: neuronal loss, gliosis, and ubiquitin-immunoreactive neuronal inclusions in affected areas. The pathological protein of the ubiquitinated inclusions in FTLD with GRN mutation has been identified as the TAR DNA-binding protein of 43 kDa (TDP-43) and TDP-43-positive aggregates are found at four sites: neuronal cytoplasmic inclusions (NCI), neuronal intranuclear inclusions (NII), dystrophic neurites (DN), and glial cytoplasmic inclusions (GCI) that are negative for tau, α-synuclein, β-amyloid and FUS (Cairns et al., 2007; Mackenzie et al., 2010) .
Progranulin is a 593 amino acid precursor protein, which is further processed to 6 kDa active peptides called granulins (Bateman and Bennett, 2009 ). In the periphery, intact progranulin is a secreted growth factor that causes tumorigenicity when overexpressed and impaired cell growth and proliferation when less abundant (Bateman and Bennett, 2009) . Moreover, progranulin and the granulins appear to have opposing effects. Progranulin functions are trophic and antiinflammatory, whereas the granulins exhibit pro-inflammatory activity (Bateman and Bennett, 2009 ). However, the physiologic function of progranulin in the CNS or the mechanism by which it leads to neurodegeneration remain open questions. Most progranulin mutations introduce a premature termination codon leading to nonsense-mediated decay with resultant absence of the mutant GRN transcript. This loss of Neurobiology of Disease 45 (2012) [395] [396] [397] [398] [399] [400] [401] [402] [403] [404] [405] [406] [407] [408] 
